GlaxoSmithKline Egypt S.A.E. specializes in the development, manufacture and marketing of medicines. Their products are for the treatment of diabetes, asthma, cancer, hepatic viruses, infections, allergies and gastro-intestinal and cardiovascular diseases.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
09/08/26	EGP 477.26	+20.00%	1,125,927
06/08/26	EGP 397.72	+20.00%	2,414,902
05/08/26	EGP 331.44	-20.00%	346,697
04/08/26	EGP 414.30	+20.00%	449,150
03/08/26	EGP 345.25	+20.00%	559,339

End-of-day quote Egyptian Exchange

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Egyptian Exchange Other stock markets 09/08/2026			5-day change	1st Jan Change
477.26 ^EGP	+20.00%		+65.88%	+649.82%

17/05	GlaxoSmithKline Q1 consol net profit EGP 4.7 million	RE
12/03	GlaxoSmithKline S.A.E Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	39.86B 800M 692M 647M 593M 1.12B 76.18B 1.13B 7.59B 2.98B 38.18B 3.01B 2.94B 126B	P/E 2024	17.3x	P/E 2025	24.9x
Enterprise Value	39.46B 792M 685M 640M 587M 1.1B 75.42B 1.12B 7.51B 2.95B 37.8B 2.98B 2.91B 125B	EV / Sales 2024	1.02x	EV / Sales 2025	1.32x
Free-Float	2.91%	Yield 2024 *	-	Yield 2025	1.57%

17/05	GlaxoSmithKline Q1 consol net profit EGP 4.7 million	RE
12/03	GlaxoSmithKline S.A.E Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12/03	GlaxoSmithKline FY dividend EGP 0.75 per share	RE
12/03	GlaxoSmithKline FY consol profit EGP 213.2 million	RE
30/12	GlaxoSmithKline S.A.E announces Annual dividend, payable on January 14, 2026	CI
19/11	GlaxoSmithKline S.A.E Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
13/11	GlaxoSmithKline Q3 consol loss EGP 34.8 million	RE
13/08/25	GlaxoSmithKline S.A.E Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
12/08/25	GlaxoSmithKline posts Q2 consol profit EGP 5.9 mln	RE
14/05/25	GlaxoSmithKline S.A.E Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
14/05/25	Glaxosmithkline Reports Q1 Net Profit EGP 43.5 Million	RE
09/03/25	GlaxoSmithKline S.A.E Reports Earnings Results for the Full Year Ended December 31, 2024	CI
09/03/25	Glaxosmithkline FY Dividend EGP 1 Per Share	RE

11/03/22	GlaxoSmithKline E : Glaxo Smith Kline (BIOC.CA) - Listing Committee Decision	PU
20/12/21	GSK hires former Tesco boss Sir Dave Lewis to head up £40bn spin-off	AQ

GlaxoSmithKline S.A.E Stock

Stocks

BIOC

EGS38171C012

Pharmaceuticals

Valuation: GlaxoSmithKline S.A.E

Chart: GlaxoSmithKline S.A.E

Latest news : GlaxoSmithKline S.A.E

Press Releases: GlaxoSmithKline S.A.E

Quotes and Performance

Course Extremes

Managers and Directors: GlaxoSmithKline S.A.E

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+20.00%
1 week	+65.88%
Current month	+99.06%
1 month	+548.45%
3 months	+563.05%
6 months	+598.67%
Current year	+649.82%

1 week	265.2	497.16
1 month	73	497.16
Current year	55.1	497.16
1 year	46.08	497.16
3 years	24.7	497.16
5 years	16.66	497.16
10 years	0	497.16

Director	Title	Age	Since
Sherine El-Ansari BRD	Director/Board Member	-	-
Ashraf Mohammed Ibrahim Mansour CHM	Chairman	-	-
Munir Ghabour Hanna BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GLAXOSMITHKLINE S.A.E	+20.00%	+65.88%	+887.09%	+1,418.97%	800M
ELI LILLY AND COMPANY	-0.52%	+3.21%	+89.52%	+125.32%	1,057B
JOHNSON & JOHNSON	+0.88%	+1.13%	+49.56%	+49.79%	625B
ABBVIE INC.	+0.89%	-1.95%	+24.23%	+63.19%	435B
ROCHE HOLDING AG	+0.71%	+3.87%	+49.07%	+38.29%	363B
NOVARTIS AG	+0.64%	-0.49%	+33.94%	+38.94%	296B
ASTRAZENECA PLC	+0.39%	-5.83%	+8.92%	+6.39%	249B
AMGEN INC.	+1.51%	+6.69%	+42.58%	+58.47%	222B
NOVO NORDISK A/S	+3.92%	-0.46%	-5.56%	-51.70%	209B
GILEAD SCIENCES, INC.	+1.80%	+2.30%	+11.56%	+66.16%	165B
Average	+3.02%	+4.67%	+119.09%	+181.38%	362.16B
Weighted average by Cap.	+0.66%	+1.34%	+48.91%	+64.15%

	2024	2025
Net sales	2.99B 60.06M 51.95M 48.52M 44.51M 83.71M 5.72B 85.04M 569M 223M 2.87B 226M 221M 9.47B	3.73B 74.92M 64.8M 60.52M 55.52M 104M 7.13B 106M 710M 279M 3.57B 281M 275M 11.81B
Net income	174M 3.49M 3.02M 2.82M 2.59M 4.87M 333M 4.95M 33.11M 13M 167M 13.12M 12.83M 551M	213M 4.28M 3.7M 3.46M 3.17M 5.97M 408M 6.06M 40.58M 15.93M 204M 16.08M 15.73M 675M
Net Debt	44.01M 884K 764K 714K 655K 1.23M 84.11M 1.25M 8.38M 3.29M 42.16M 3.32M 3.25M 139M	-398M -7.99M -6.91M -6.46M -5.92M -11.14M -761M -11.32M -75.74M -29.73M -381M -30.01M -29.35M -1.26B